Physician profile
Phyillis A Kennedy-Howell
NPI 1063951408
$672,566.51
in general payments reported to CMS, 2019-2025
5 companies · $224K in 2025
The $224K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $497 · 2022: $78K · 2023: $180K · 2024: $190K · 2025: $224K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $461K · Travel and Lodging: $104K · Consulting Fee: $17K · Food and Beverage: $12K · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $461,475.18 |
| Travel and Lodging | $103,559.52 |
| Consulting Fee | $16,670.50 |
| Food and Beverage | $12,155.09 |
| Education | $217.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $290,800.05 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $193,459.24 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $184,356.54 | 2021-2025 | Nuplazid |
| Mylan Specialty L.P. | $3,705.20 | 2022-2024 | Yupelri, Yupelri |
| Otsuka America Pharmaceutical, INC. | $245.48 | 2023-2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyillis Kennedy-Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.